secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001437749-23-023680
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q2 net loss $12.4M; cash $11.2M; Phase 3 schizophrenia data due Oct 2023
-------------------------------------------------------------------------------

- Net loss of $12.4M ($0.55 per share) for Q2 2023 vs $5.3M ($0.29) a year ago.
- Cash $11.2M as of June 30, 2023, down from $18.5M at Dec 2022; runway into Q4 2023.
- Topline data for pivotal Phase 3 RECOVER trial of brilaroxazine in schizophrenia expected October 2023.
- Enrollment near completion (~400 patients); 1-year OLE study completion expected Q3 2024.
- May initiate Phase 2a studies in bipolar, MDD, ADHD in H2 2023 subject to additional financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/0001437749-23-023680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923023680/rvph20230809_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer